Corrie Nunan Lui, PA
Physician Assistant · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
Offices
2 locations · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Looking this up.
Hospitals listed: California Pacific Medical Center- Van Ness Campus. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Corrie Nunan Lui’s office at (415) 600-1020 to ask if they take your plan before you enroll.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- California Pacific Medical Center- Van Ness CampusSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.224, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.325, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.373, Oct 2024 – Sep 2025
See every measure and the patient survey for California Pacific Medical Center- Van Ness Campus
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 0 better, 8 the same, 2 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.224 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.325 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.373 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.14 (0.3 to 1.97) · 2,271 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.81 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 192.86 (151.51 to 234.22) · 140 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 10.3 · 60 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.5 · 143 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.8 · 356 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.3 · 259 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 173 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.1 · 2,316 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.31 (0.12 to 0.49) · 6,430 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.09 to 0.47) · 7,168 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.3 (1.5 to 5.09) · 2,196 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.47 (1.21 to 3.74) · 925 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.63 (1.37 to 3.88) · 1,954 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.13 (6.06 to 14.2) · 1,112 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.26 (4.67 to 9.85) · 1,084 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.67 (0.31 to 3.03) · 832 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.33 (0 to 0.85) · 5,406 cases | No different | Jul 2022 – Jun 2024 |
| MRSA BacteremiaInfections | 0.443 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.717 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 200 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.3 · 449 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 18.2 · 187 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 8.7 · 418 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 7.1 · 260 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19.2 · 293 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (3.6 to 7.6) · 157 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.2 (7.7 to 13.5) · 157 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 11 · 33 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.2 · 66 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.5 (9.4 to 16.7) · 551 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.3) · 219 cases | No different | Jan 2024 – Dec 2024 |
What patients said (478 patients answered, 20% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 74% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 70% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
Original Medicare doctor bills
$506,160
Medicare paid this office $506,160 for 256 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection, romosozumab-aqqg, 1 mg | 22 | $275,392 | None |
| Injection, denosumab, 1 mg | 97 | $202,416 | None |
| Return visit (30+ min) | 87 | $12,463 | $97 |
| Short return visit (20+ min) | 80 | $6,344 | $67 |
| Injection of drug or substance under skin or into muscle | 121 | $5,705 | $12 |
See all 6 services
| Injection, romosozumab-aqqg, 1 mg | 22 | $275,392 | None |
| Injection, denosumab, 1 mg | 97 | $202,416 | None |
| Return visit (30+ min) | 87 | $12,463 | $97 |
| Short return visit (20+ min) | 80 | $6,344 | $67 |
| Injection of drug or substance under skin or into muscle | 121 | $5,705 | $12 |
| Hemoglobin a1c level | 36 | $438 | $10 |
Who their Medicare patients are
256 Original Medicare patients in 2024. Average age 75 · Under 65 6% · 85 and older 15% · Women 81% · Also on Medicaid 22% · Health risk score 1.49. Above the middle of the specialty; the typical physician assistant clinician is at 1.31.
Conditions among them: High blood pressure 72% · Diabetes 45% · Chronic kidney disease 33% · Depression 25% · Coronary heart disease 23% · Atrial fibrillation 19% · Cancer 18% · Heart failure 12% · COPD 11% · Dementia 7% · Stroke 4%.
The office billed $1,398,986, Medicare allowed $637,894 and paid $506,160; for 42,789 services of 10 kinds; $481,132 of it was for drugs given in the office and $25,028 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 256 | 42,789 | 75 | 1.49 | $1,398,986 | $506,160 |
| 2023 | 229 | 26,052 | 74 | 1.29 | $720,872 | $315,655 |
| 2022 | 190 | 22,072 | 75 | 1.41 | $642,653 | $267,815 |
| 2021 | 176 | 10,414 | 75 | 1.57 | $444,369 | $166,635 |
| 2020 | 130 | 7,838 | 74 | 1.47 | $296,326 | $111,517 |
| 2019 | 173 | 6,108 | 72 | 1.43 | $293,186 | $93,399 |
| 2018 | 120 | 3,726 | 71 | 1.62 | $192,317 | $61,004 |
| 2017 | 113 | 1,273 | 70 | 1.62 | $99,938 | $26,726 |
| 2016 | 115 | 1,745 | 71 | 1.71 | $117,569 | $31,152 |
| 2015 | 135 | 930 | 69 | 1.70 | $88,602 | $21,956 |
| 2014 | 128 | 1,322 | 69 | 1.57 | $105,157 | $27,588 |
| 2013 | 123 | 731 | 69 | 1.67 | $78,317 | $19,611 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 7 services
| Injection, denosumab, 1 mg | 86 | $158,030 | None |
| Injection, romosozumab-aqqg, 1 mg | 15 | $133,100 | None |
| Return visit (30+ min) | 74 | $9,826 | $92 |
| Short return visit (20+ min) | 76 | $6,553 | $66 |
| Injection of drug or substance under skin or into muscle | 105 | $3,690 | $12 |
| Hemoglobin a1c level | 51 | $619 | $10 |
| Blood glucose (sugar) test performed by hand-held instrument | 13 | $51 | $3 |
2022: 7 services
| Injection, denosumab, 1 mg | 89 | $154,422 | None |
| Injection, romosozumab-aqqg, 1 mg | 11 | $93,481 | None |
| Return visit (30+ min) | 57 | $8,179 | $97 |
| Short return visit (20+ min) | 44 | $3,939 | $67 |
| Injection of drug or substance under skin or into muscle | 106 | $2,662 | $11 |
| Hemoglobin a1c level | 33 | $432 | $10 |
| Blood glucose (sugar) test performed by hand-held instrument | 11 | $45 | $3 |
2021: 6 services
| Injection, denosumab, 1 mg | 79 | $139,107 | None |
| Return visit (30+ min) | 55 | $6,943 | $91 |
| Short return visit (20+ min) | 38 | $2,982 | $66 |
| Injection of drug or substance under skin or into muscle | 84 | $1,710 | $11 |
| Telephone medical discussion with physician, 11-20 minutes | 22 | $1,138 | $46 |
| Hemoglobin a1c level | 25 | $291 | $10 |
2020: 7 services
| Injection, denosumab, 1 mg | 60 | $81,432 | None |
| Return visit (30+ min) | 31 | $2,979 | $74 |
| Telephone medical discussion with physician, 21-30 minutes | 16 | $1,572 | $87 |
| Telephone medical discussion with physician, 11-20 minutes | 16 | $963 | $57 |
| Online digital evaluation and management service for an established patient for up to 7 days, total time 21 or more minutes | 19 | $860 | $39 |
| Short return visit (20+ min) | 13 | $794 | $53 |
| Injection of drug or substance under skin or into muscle | 32 | $464 | $12 |
2019: 6 services
| Injection, denosumab, 1 mg | 52 | $73,486 | None |
| Return visit (30+ min) | 81 | $11,132 | $76 |
| Short return visit (20+ min) | 66 | $5,573 | $56 |
| Injection of drug or substance under skin or into muscle | 25 | $391 | $14 |
| Hemoglobin a1c level | 11 | $148 | $11 |
| Blood glucose (sugar) test performed by hand-held instrument | 31 | $119 | $3 |
2018: 6 services
| Injection, denosumab, 1 mg | 36 | $48,933 | None |
| Return visit (30+ min) | 43 | $5,268 | $75 |
| Short return visit (20+ min) | 49 | $3,170 | $49 |
| Injection of drug or substance under skin or into muscle | 29 | $550 | $17 |
| Administration of influenza virus vaccine | 12 | $303 | $25 |
| Blood glucose (sugar) test performed by hand-held instrument | 17 | $67 | $3 |
2017: 5 services
| Injection, denosumab, 1 mg | 14 | $13,642 | None |
| Return visit (30+ min) | 60 | $7,279 | $76 |
| Short return visit (20+ min) | 62 | $4,431 | $50 |
| Injection of drug or substance under skin or into muscle | 16 | $396 | $22 |
| Blood glucose (sugar) test performed by hand-held instrument | 16 | $54 | $3 |
2016: 5 services
| Injection, denosumab, 1 mg | 22 | $18,717 | None |
| Return visit (30+ min) | 45 | $6,131 | $76 |
| Short return visit (20+ min) | 59 | $4,753 | $49 |
| Injection of drug or substance under skin or into muscle | 22 | $534 | $21 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 11 | $187 | $17 |
2015: 4 services
| Return visit (30+ min) | 61 | $7,271 | $77 |
| Short return visit (20+ min) | 74 | $5,682 | $53 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 19 | $459 | $16 |
| Hemoglobin a1c level | 12 | $194 | $13 |
2014: 5 services
| Injection, denosumab, 1 mg | 14 | $11,274 | None |
| Return visit (30+ min) | 64 | $7,769 | $78 |
| Short return visit (20+ min) | 75 | $7,065 | $54 |
| Injection of drug or substance under skin or into muscle | 13 | $366 | $20 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 11 | $219 | $17 |
2013: 4 services
| Return visit (30+ min) | 67 | $7,955 | $77 |
| Short return visit (20+ min) | 62 | $5,116 | $54 |
| Short return visit | 13 | $502 | $31 |
| Hemoglobin a1c level | 11 | $171 | $13 |
Drugs they prescribed that Part D paid
$159,656
Pharmacies billed $159,656 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 278) in 2024. At or below the middle of the specialty; the typical physician assistant clinician is at 1%.
111 generic and 145 brand-name prescriptions · $159,656 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Ozempic | 20 | $25,930 | $1,297 |
| Jardiance | 20 | $11,796 | $590 |
| Testosterone | 28 | $8,438 | $301 |
| Janumet Xr | 12 | $6,042 | $503 |
| Synthroid | 18 | $1,250 | $69 |
See all 8 drugs
| Ozempic | 20 | $25,930 | $1,297 |
| Jardiance | 20 | $11,796 | $590 |
| Testosterone | 28 | $8,438 | $301 |
| Janumet Xr | 12 | $6,042 | $503 |
| Synthroid | 18 | $1,250 | $69 |
| Lantus Solostar | 11 | $970 | $88 |
| Testosterone Cypionate | 13 | $294 | $23 |
| Metformin Hcl Er | 12 | $211 | $18 |
Year by year
| 2024 | 278 | 69 | 0% (0) | 52% | $159,656 |
| 2023 | 250 | 68 | 0% (0) | 40% | $135,045 |
| 2022 | 218 | 54 | 0% (0) | None | $95,320 |
| 2021 | 213 | 68 | 0% (0) | 29% | $88,884 |
| 2020 | 212 | 78 | 0% (0) | 31% | $85,421 |
| 2019 | 254 | 88 | 0% (0) | 44% | $155,271 |
| 2018 | 320 | 79 | 0% (0) | 51% | $201,600 |
| 2017 | 288 | 74 | 0% (0) | 48% | $130,991 |
| 2016 | 334 | 72 | None | 55% | $108,891 |
| 2015 | 416 | 84 | 0% (0) | 51% | $121,433 |
| 2014 | 390 | 101 | None | 53% | $117,919 |
| 2013 | 393 | 105 | None | 60% | $126,936 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 8 drugs
| Novolog Flexpen | 17 | $21,846 | $1,285 |
| Testosterone | 38 | $19,039 | $501 |
| Omnipod 5 G6 Pods (Gen 5) | 11 | $18,146 | $1,650 |
| Lantus Solostar | 12 | $10,884 | $907 |
| Testosterone Cypionate | 26 | $716 | $28 |
| Synthroid | 11 | $606 | $55 |
| Metoprolol | 12 | $265 | $22 |
| Levothyroxine | 11 | $229 | $21 |
2022: 3 drugs
| Trulicity | 17 | $20,857 | $1,227 |
| Testosterone | 39 | $14,701 | $377 |
| Testosterone Cypionate | 34 | $842 | $25 |
2021: 4 drugs
| Testosterone | 62 | $29,942 | $483 |
| Trulicity | 23 | $25,928 | $1,127 |
| Testosterone Cypionate | 29 | $1,438 | $50 |
| Levothyroxine | 13 | $179 | $14 |
2020: 3 drugs
| Testosterone | 31 | $18,567 | $599 |
| Testosterone Cypionate | 29 | $1,315 | $45 |
| Levothyroxine | 14 | $412 | $29 |
2019: 5 drugs
| Testosterone | 30 | $32,105 | $1,070 |
| Androderm | 11 | $8,982 | $817 |
| Ultra-Fine Mini Pen Needle | 14 | $1,365 | $97 |
| Testosterone Cypionate | 26 | $829 | $32 |
| Metformin | 13 | $121 | $9 |
2018: 8 drugs
| Forteo | 16 | $56,903 | $3,556 |
| Humalog Kwikpen U-100 | 17 | $31,767 | $1,869 |
| Androgel | 16 | $28,417 | $1,776 |
| Novolog Flexpen | 12 | $7,170 | $598 |
| Testosterone | 12 | $5,836 | $486 |
| Testosterone Cypionate | 29 | $592 | $20 |
| Atorvastatin | 15 | $239 | $16 |
| Metformin | 18 | $215 | $12 |
2017: 8 drugs
| Androgel | 24 | $28,535 | $1,189 |
| Lyrica | 13 | $9,352 | $719 |
| Novolog Flexpen | 11 | $8,531 | $776 |
| Lantus Solostar | 15 | $5,558 | $371 |
| Testosterone Cypionate | 18 | $757 | $42 |
| Valsartan | 11 | $253 | $23 |
| Metformin | 11 | $171 | $16 |
| Hydrochlorothiazide | 12 | $44 | $4 |
2016: 11 drugs
| Lantus | 11 | $15,081 | $1,371 |
| Novolog Flexpen | 17 | $11,622 | $684 |
| Januvia | 25 | $9,088 | $364 |
| Lantus Solostar | 20 | $6,945 | $347 |
| Levemir Flextouch | 11 | $4,493 | $408 |
| Crestor | 13 | $4,103 | $316 |
| Bd Ultra-Fine Pen Needle | 13 | $772 | $59 |
| Testosterone Cypionate | 21 | $640 | $30 |
| Levothyroxine | 15 | $515 | $34 |
| Glipizide | 25 | $275 | $11 |
| Metformin | 12 | $56 | $5 |
2015: 14 drugs
| Androgel | 19 | $22,253 | $1,171 |
| Januvia | 32 | $13,108 | $410 |
| Lantus Solostar | 14 | $5,967 | $426 |
| Tradjenta | 13 | $4,358 | $335 |
| Synthroid | 24 | $1,175 | $49 |
| Bd Ultra-Fine Pen Needle | 20 | $1,134 | $57 |
| Levothyroxine | 22 | $489 | $22 |
| Glyburide | 12 | $375 | $31 |
| Testosterone Cypionate | 13 | $347 | $27 |
| Hydrochlorothiazide | 11 | $159 | $14 |
| Gabapentin | 17 | $157 | $9 |
| Glipizide | 14 | $135 | $10 |
| Methimazole | 11 | $133 | $12 |
| Alendronate | 13 | $46 | $4 |
2014: 13 drugs
| Humalog | 14 | $13,159 | $940 |
| Januvia | 18 | $7,891 | $438 |
| Lantus | 13 | $7,586 | $584 |
| Novolog Flexpen | 18 | $6,241 | $347 |
| Synthroid | 18 | $1,319 | $73 |
| Dyrenium | 11 | $1,238 | $113 |
| Bd Ultra-Fine Pen Needle | 21 | $1,071 | $51 |
| Atorvastatin | 14 | $581 | $41 |
| Glyburide | 15 | $336 | $22 |
| Metformin | 12 | $286 | $24 |
| Levothyroxine | 14 | $270 | $19 |
| Glipizide | 24 | $202 | $8 |
| Lisinopril | 11 | $131 | $12 |
2013: 11 drugs
| Forteo | 12 | $28,127 | $2,344 |
| Androgel | 15 | $15,840 | $1,056 |
| Januvia | 23 | $10,840 | $471 |
| Humalog | 31 | $10,620 | $343 |
| Lantus | 24 | $7,712 | $321 |
| Lantus Solostar | 24 | $6,722 | $280 |
| Novolog Flexpen | 13 | $5,908 | $454 |
| Bd Ultra-Fine Pen Needle | 21 | $1,568 | $75 |
| Levothyroxine | 25 | $340 | $14 |
| Metformin | 20 | $281 | $14 |
| Glipizide | 18 | $236 | $13 |
Money from drug and device companies
$173 in 2025
| 2025 | 4 | 7 | None | $173 |
| 2024 | 2 | 4 | None | $90 |
| 2023 | 4 | 20 | None | $770 |
| 2022 | 3 | 5 | None | $144 |
| 2021 | 3 | 3 | None | $45 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Sequel Med Tech | Twiist | $65 | 2 payments
|
| Dexcom | Dexcom G6 Transmitter | $63 | 3 payments
|
| Medtronic | Minimed 780g | $25 | 1 payment
|
| Tandem Diabetes Care | T:Slim X2 Insulin Pump With Control-Iq | $20 | 1 payment
|
See all 7 published payments
| Dexcom | Meals · 2025-12-23 | Dexcom G6 Transmitter | $24 |
| Medtronic | Meals · 2025-10-28 | Minimed 780g | $25 |
| Sequel Med Tech | Meals · 2025-09-30 | Twiist | $38 |
| Dexcom | Meals · 2025-08-12 | Dexcom G6 Transmitter | $24 |
| Tandem Diabetes Care | Meals · 2025-04-29 | T:Slim X2 Insulin Pump With Control-Iq | $20 |
| Dexcom | Meals · 2025-03-31 | Dexcom G6 Transmitter | $14 |
| Sequel Med Tech | Meals · 2025-03-18 | Twiist | $27 |
See earlier years (2024, 2023, 2022, 2021)
2024: $90
| Dexcom | Dexcom G6 Transmitter | $67 | 3 payments
|
| Tandem Diabetes Care | T:Slim X2 Insulin Pump With Control-Iq | $23 | 1 payment
|
2023: $770
| Dexcom | Dexcom G6 Transmitter | $492 | 11 payments
|
| CeQur | Cequr Simplicity | $185 | 1 payment
|
| Beta Bionics | Ilet Bionic Pancreas | $57 | 3 payments
|
| Tandem Diabetes Care | T:Slim X2 Insulin Pump With Control-Iq | $35 | 2 payments
|
2022: $144
| Dexcom | Dexcom G6 Transmitter | $94 | 2 payments
|
| Insulet | Omnipod | $38 | 2 payments
|
| Lilly USA | None | $12 | 1 payment
|
2021: $45
| E.R. Squibb & Sons L.L.C. | Opdivo | $16 | 1 payment
|
| Dexcom | Dexcom G6 Transmitter | $15 | 1 payment
|
| Amgen | None | $14 | 1 payment
|
Professional record
- NPI
- 1548227507
- Licence
- CA 14939
- Trained
- Stanford University School of Medicine, 1999
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Medicaid ID
- CA PA14939
- Taxonomy
- Physician assistant (363A00000X)
- Mailing address
- 1635 Divisadero St, Ste 625, Box 1821, San Francisco, CA, 94143
- NPI first listed
- 2006-04-26
- NPI last updated
- 2022-11-03
- NPI record certified
- 2022-11-03
This is when the NPI record was last certified, not a medical board exam.